Dapagliflozin Therapy In Cardiac Surgery
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 178 participants.
Also called NCT05621551
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 178 participants
- Registry
-
NCT05621551
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT05621551. Randomized; single masking; primary purpose treatment. Start 2022-11-11 (actual); primary completion 2024-06-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Dapagliflozin Therapy In Cardiac Surgery
- Condition
- Diabetes Mellitus, Type 2
- Condition
- Cardiac Surgery
- Intervention (Drug)
- Dapagliflozin
- Lead sponsor
- China National Center for Cardiovascular Diseases
Record details
- Record id
cardio:ct-nct05621551- Content hash
deb26f6ec2e09b4bb59a3f9d31a08e68d9d133ecb275bc039c3be5ad87f32e0c